SignalChem Lifesciences Corp. Obtains NOL from Health Canada for Clinical Trial of AXL Inhibitor SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
VANCOUVER, BC — SignalChem Lifesciences Corp. today announced that it has received a No Objection Letter (NOL) from Health Canada for its clinical trial “A Single-Arm, Open-Label, Phase 1b/2 Study… Read More




